NCT06126263View on ClinicalTrials.gov

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

Active, not recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

June 30, 2024

Conditions
Streptococcal SepsisInvasive Group A Beta-Haemolytic Streptococcal DiseaseNecrotizing Soft Tissue InfectionInfection, BloodstreamInfection, BacterialStreptococcal Toxic Shock Syndrome
Interventions
DRUG

Linezolid

Adjunctive antitoxin therapy

DRUG

Clindamycin

Adjunctive antitoxin therapy

Trial Locations (1)

20892

National Institutes of Health Clinical Center (primary center conducting large database study), Bethesda

All Listed Sponsors
collaborator

Emory University

OTHER

lead

National Institutes of Health Clinical Center (CC)

NIH